Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay

Publisher： John Wiley & Sons Inc

E-ISSN： 1749-6632|1346|1|7-17

ISSN： 0077-8923

Source： ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, Vol.1346, Iss.1, 2015-06, pp. : 7-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CCR5 as a Natural and Modulated Target for Inhibition of HIV

By Burke Bryan P.   Boyd Maureen P.   Impey Helen   Breton Louis R.   Bartlett Jeffrey S.   Symonds Geoff P.   Hütter Gero  

Viruses, Vol. 6, Iss. 1, 2013-12 ,pp. : 54-68

MDPI

Access to resources Recommend Favorite

CCR5: From Natural Resistance to a New Anti-HIV Strategy

By Lopalco Lucia  

Viruses, Vol. 2, Iss. 2, 2010-02 ,pp. : 574-600

MDPI

Access to resources Recommend Favorite

High levels of CC‐chemokine expression and downregulated levels of CCR5 during HIV‐1/HTLV‐1 and HIV‐1/HTLV‐2 coinfections

By  

JOURNAL OF MEDICAL VIROLOGY, Vol. 87, Iss. 5, 2015-05 ,pp. : 790-797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Allelic distribution of the CCR5, CCR2, and SDF1 gene polymorphisms associated with HIV-1/AIDS resistance in Russian populations

By Kofiadi I.   Rebrikov D.   Trofimov D.   Alexeev L.   Khaitov R.  

Doklady Biological Sciences, Vol. 415, Iss. 1, 2007-08 ,pp. : 320-323

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite

Patterns of Diversity in HIV-Related Loci among Subspecies of Chimpanzee: Concordance at CCR5 and Differences at CXCR4 and CX3CR1

By MacFie T.S.   Nerrienet E.   de Groot N.G.   Bontrop R.E.   Mundy N.I.  

Molecular Biology and Evolution, Vol. 26, Iss. 4, 2009-04 ,pp. : 719-727

Oxford University Press

Access to resources Recommend Favorite